TABLE 2.
Vaccine strategies | Mechanism | LAB strain | Antigen | Administration route | Immune responses | Protection |
---|---|---|---|---|---|---|
Co‐expression of targeting molecules | ||||||
Dendritic cells targeting peptides and antibodies: DCpep, scFv‐CD11c, scFv‐DEC205 | Promote the maturation of DCs and enhance antigen uptake by DCs. | Lactobacillus casei | E2 protein of bovine viral diarrhea virus | Oral | Serum antibody, mucosal antibody in intestinal mucus and feces, neutralizing activity and cytokines of IFN‐γ and IL‐4 | Eliminate the virus from intestine, lung, blood, and spleen.[ 40 ] |
Lactobacillus plantarum | NP and M1 protein of avian influenza virus | Oral | Fecal and BALF IgA antibody and IFN‐γ‐producing T‐cells | Provide 80% and 60% protection rate against homologous and heterologous virus infection, respectively.[ 42 ] | ||
Lactobacillus plantarum | Hemagglutinin protein of Influenza A virus (H1N1) | Oral | Serum IgG, BALF and fecal IgA, neutralizing antibody, B220+IgA+ B cells in PP and IFN‐γ‐producing T‐cells | Increase survival of immunized mice after influenza virus challenge.[ 43 ] | ||
M cells targeting peptides or proteins: Col, CKS9, OmpH. | Enhance the effectiveness of antigen delivery through the intestinal mucosa. | Lactobacillus saerimneri | OmpC and FimA proteins of avian pathogenic Escherichia coli | Oral | Antigen‐specific serum IgG and SIgA in cecum, nasal cavity, and feces | 80% immunized chicken survived after avian E. coli challenges.[ 47 ] |
Lactococcus lactis | Viral capsid protein (VP)2 antigen of infectious bursal disease virus |
Oral Intramuscular |
Neutralizing antibody and mucosal SIgA antibody | Provide complete protection by injection and 80% protection rate by oral.[ 51 ] | ||
Intestinal epithelial cells targeting proteins: FnBPA | Improve the delivery ability and increase antigen uptake by lymphocytes | Lactococcus lactis | E7 antigen of human papillomavirus16 | Intranasal | IgG2a systemic and IgA mucosal immune responses and CTL | Reduce tumor development.[ 56 ] |
Cytokines | ||||||
IL‐12 | Stimulate activity of cytotoxic T lymphocytes and natural killer (NK)‐cells; promote IFN‐γ production.[ 57 ] | Lactococcus lactis | E7 antigen of human papillomavirus16 | Intranasal | ELISPOT: IFN‐γ‐secreting T‐cells[ ]; E7‐specific CTL response, cytokines of IL‐12 and IFN‐γ[ 59 ] | Increase survival rates and regress tumor growth.[ 58 , 59 ] |
Lactococcus lactis |
Leishmania antigen LACK |
Oral | IgA antibodies in intestinal washes and a systemic Th1 immune response | No report[ 60 ] | ||
IL‐2 | Induce the proliferation of immune cells and the differentiation of effector CD4+T cells.[ 63 ] | Lactococcus lactis | UreB protein of Helicobacter pylori | Oral | Serum antibody, fecal IgA and serum IFN‐γ, IL‐4, and IL‐17 | Accelerate H. pylori clearance and reduce the levels of H. pylori colonization in the stomach.[ 65 ] |
IL‐6 | Promote the secretion of antibodies by maturated B cells and the production of IL‐2.[ 68 ] | Lactococcus lactis | Tetanus toxin fragment C | Intranasal | anti‐TTFC IgG and IgA responses | No report[ 69 ] |
Lactococcus lactis | Brachyspira membrane protein B | Oral | Serum IgG, IgG1, and IgG2a, feces and intestinal IgA, IL‐4, IFN‐γ, and IL‐2‐secreting lymphocytes in PPs | No report[ 49 ] | ||
Mucosal adjuvant | ||||||
Cholera toxin | Induce the polarization of T cells towards Th2 and B cells activated and isotype switching. | Lactococcus lactis | Influenza virus nucleoprotein | Oral | Serum antibody, mucosal IgA in intestine and upper respiratory washes, and IFN‐γ and IL‐4 secreting splenocytes | Improve the resistance to divergent influenza viruses challenge.[ 74 ] |
Lactobacillus casei | Matrix protein‐2 of influenza virus | Oral Intranasal | Serum IgG, IgA antibody in lung and intestine, and IFN‐γ and IL‐4 secreting splenocytes | Decrease virus titers in the lung tissues after challenge with influenza virus.[ 76 ] | ||
Heat‐labile enterotoxin | Induces mixed Th1 and Th2 immune responses and B cells and DCs activation. | Lactobacillus casei | VP4 antigen of porcine rotavirus | Oral | Serum IgG, specific IgA in ophthalmic, vaginal wash and feces, neutralization activity | No report[ 80 ] |
Lactobacillus casei | F4 (K88) fimbrial adhesin FaeG of enterotoxigenic Escherichia coli | Oral | SIgA in feces, vaginal lavage, and nasal lavage, serum antibody, and lymphocyte proliferation | Provide complete protection to immunized mice.[ 83 ] | ||
Flagellin | Toll‐like receptor 5 agonist, stimulate the activation of NF‐kB, the maturation of DCs[ 85 ] | Lactobacillus acidophilus | Gag protein of HIV‐1 | Oral | IgA‐secreting and IFN‐γ‐producing lymphocytes from Peyer's patches, female reproductive tract, and large intestine | No report[ 87 ] |
Polymer's coating | ||||||
Enteric‐coated capsules | Improve the stability and viability of LAB in the gastrointestinal tract | Lactococcus lactis | Hemagglutinin protein of H5N1 | Oral | Serum IgG and fecal IgA, IFN‐γ secreting splenocytes | Provide full immune protection against H5N1 virus challenges[ 96 ] |
Alginate/chitosan/alginate microcapsules | Lactobacillus plantarum | Brachyspira membrane protein B | Oral | Serum IgG, IgG1, and IgG2a, feces, and intestinal IgA | No report[ 97 ] |